Appropriate dose of regorafenib based on body weight of colorectal cancer patients: a retrospective cohort study.

ABSTRACT:

Purpose

Previous randomized studies have shown a survival benefit of using regorafenib but a high rate of adverse events in unresectable colorectal cancer patients. To reduce these adverse events and improve the tolerability, we examined the appropriate dose of regorafenib based on body weight.

Methods

We used a nationwide claims database in Japan and examined the efficacy and safety of regorafenib for patients with metastatic colorectal cancer between groups divided by body weight (60 kg) and median average dose (120 mg) between 2013 and 2018. We also assessed overall survival (OS) and adverse events between these groups.

Results

We identified 2530 Japanese patients (heavy weight/high dose: 513, light weight/low dose: 921, heavy weight/low dose: 452, and light weight

SUBMITTER: Nakashima M 

PROVIDER: S-EPMC10740272 | biostudies-literature | 2023 Dec

REPOSITORIES: biostudies-literature